WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT.
A live webcast of the presentation will be available at https://wsw.com/webcast/jeff315/cresc/1987776. An archived recording will be available for 90 days following the event.
In late October, Crescent entered into an acquisition agreement with Rockville, Maryland-based GlycoMimetics, Inc. (NASDAQ: GLYC). Following closing, the combined company will operate under the name Crescent and advance its portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors.
About Crescent Biopharma
Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. The company's pipeline of three programs harnesses proven biology to accelerate the path to market for potentially best-in-class therapeutics. For more information, visit www.crescentbiopharma.com.
Media Contact:
Deerfield Group
Lia Dangelico
540-303-0180
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Argot Partners
Dawn Schottlandt
212-600-1902
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.26 |
| Daily Change: | 0.001 0.39 |
| Daily Volume: | 238,403 |
| Market Cap: | US$16.780M |
November 06, 2024 October 29, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
